Background
This ruling forms part of a wider piece of work on prescription-only medicines (POMs) used for weight loss. See also related rulings published on 9 July 2025, 17 December 2025, 11 February 2026, 18 February 2026, 8 April 2026, 27 May 2026, 24 June 2026 and 9 July 2026.
Summary of Council decision:
Two issues were investigated, both of which were Upheld.
Ad description
Two paid-for Facebook ads from UK Weight Loss Reviews, seen on 1 April 2026.
a. The first ad featured the caption, “Why overpay for weight loss treatments? Bolt Pharmacy offers genuine weight loss treatments at rock-bottom prices – safely and conveniently online. *Weight loss treatments are prescription-only and subject to approval. Individual results may vary. Always consult with a qualified professional before starting any weight loss treatment”,
The ad featured a video. On-screen text and a voice-over stated, “UK’s best-price weight loss treatment, didn’t think it could get better. Most weight loss programmes charge hundreds per month, and that’s exactly how they want it. The industry profits by keeping you subscribed, not by helping you succeed. That’s why Bolt offers the UK’s best pricing, with transparent costs, no hidden fees, no monthly traps. Science-backed treatment. Rapid delivery with constant support. Whether you’ve wasted money on expensive programmes, or you’re starting fresh, Bolt gives you real value and real results. Take the 2 minute quiz and see if you qualify.”
The video featured a comparison chart titled “Price VS”. It featured two vertical bars: a short white bar labelled “Bolt” with one cash emoji above it, and a taller black bar labelled “Others”, with three cash emojis above it.
Text at the bottom of the ad stated, “Join Thousands of UK Customers Saving with Bolt Pharmacy. The UK’s most affordable weight loss meds. Learn More”.
b. The second ad featured the caption, “Most people don’t realise they’re paying far more than they need to for weight loss treatments. Bolt Pharmacy gives you the same trusted, UK-regulated medications at the UK’s lowest prices. Fast online consultation, discreet delivery, and no hidden fees…”.
The ad featured a video. A woman stated, “I’ve been using Bolt and what the. I’ve literally not felt like this since I was in high school. This was like a couple of months ago, and I was like, this prices of these weight loss meds are ridiculous. We’re not paying that anymore. So I looked into it and found Bolt. They’ve actually got the best price in the UK. If you don’t know about them, get to know, because, wow. I got my mum started on it and signed myself up too. I was like, I got to try this, 2026 right? You just do a two-minute quiz to see if you’re eligible. It’s free shipping and you don’t need to be doing mental workout routines or anything extreme. Me and my mum are both buzzing with it now. I’ll place the link down here, so the sooner you get it the sooner you’ll be looking great.”
Text at the bottom of the ad stated, “Join Thousands of UK Customers Saving with Bolt Pharmacy. Learn More”.
Issue
The ASA challenged whether:
1. by implying they were from an independent review site, the ads falsely implied that the marketer was acting for purposes outside its business and did not make clear their commercial intent; and
2. the ads breached the Code because they promoted POMs to the public.
Response
1. & 2. Bolt Healthcare Ltd t/a Bolt Pharmacy confirmed that they operated the UK Weight Loss Reviews Facebook page. They acknowledged that the presentation of the page did not make sufficiently clear its commercial relationship with Bolt Pharmacy, and may have misled consumers. They said that all ads from the page had been stopped, and they were reviewing their use of the page in the future.
Bolt Pharmacy acknowledged that the use of an age gate may not have been a sufficient barrier to prevent POMs from being promoted to the public. They said they had made changes to their advertising and user journeys, to ensure that ads focused on the clinical service only.
Bolt Pharmacy said they took their regulatory obligations seriously and had updated their marketing practices to align with MHRA (Medicines and Healthcare products Regulatory Agency) guidance.
Assessment
1. Upheld
The CAP Code prohibited marketers from implying that they were acting for purposes outside their trade, business, craft or profession. It also required that ads must make their commercial intent clear.
The ASA considered that consumers would understand from the name “UK Weight Loss Reviews” that it was an independent organisation that provided unbiased reviews on weight-loss products in the UK. The ads provided general information about Bolt Pharmacy’s service including some claims regarding its prices compared to other providers. For example, ad (a) stated “UK’s best-price weight loss treatment”, and (b) stated “the UK’s lowest prices”. In the context of the account name “UK Weight Loss Reviews”, we considered those claims comparing Bolt’s prices with other providers in the market added to the impression that the ads had been placed by an independent review site that compared weight-loss products.
However, we understood that was not the case, that Bolt Pharmacy operated UK Weight Loss Reviews and had therefore posted the ads.
Because the ads gave the impression that they were from an independent review site and did not make clear that UK Weight Loss Reviews was owned and operated by Bolt Pharmacy, we concluded they falsely implied Bolt Pharmacy was acting for purposes outside its business and did not make clear their commercial intent.
On that point, the ads breached CAP Code (Edition 12) rule 2.3 (Recognition of marketing communications).
2. Upheld
The CAP Code stated that POMs or prescription-only medical treatments must not be advertised to the public.
Ad (a) featured the text, “Bolt Pharmacy offers genuine weight loss treatments […] *Weight loss treatments are prescription-only and subject to approval”. We considered that the reference to “Weight loss treatments” that were “prescription-only” promoted POMs to the public.
We understood that Chapter seven of the MHRA’s ‘The Blue Guide’ stated that a website homepage should focus on medical conditions and the service the website provided, and not include any reference to named POMs. It said that links and navigation aids may be given for particular conditions and diseases but not be specific to POMs. The guidance said that further pages about the condition, which consumers chose to access, may contain non-promotional information on specific medicines provided that was presented in the context of a fair overview of the treatment options.
We understood that landing pages from paid-for ads on social media were akin to a homepage, for the purposes of The Blue Guide. We noted that both ads linked through to an age gate. We considered the age gate functioned as a means of asking the user to confirm that they were old enough to use the site’s services before continuing to the landing page.
The landing page for both ads included the text “Wegovy for Weight Loss” and “Mounjaro for Weight Loss” below images of branded injection pens. We understood Wegovy (semaglutide) and Mounjaro (tirzepatide) were classed as POMs.
We considered that consumers who had clicked through to the landing page were actively presented with POMs, as opposed to information about particular conditions and diseases. We therefore considered that because the landing page linked to from the ads, via an age gate, referenced POMs, the ad promoted POMs to the public.
We sought advice from the MHRA. They expressed concern that the ads were likely to lead to the use of a POM.
For those reasons, we considered the ads promoted POMs to the public and concluded that they breached the Code.
On that point, the ads breached CAP Code (Edition 12) rule 12.12 (Medicines, medical devices, health-related products and beauty products).
Action
The ads must not appear again in the form complained of. We told Bolt Healthcare Ltd t/a Bolt Pharmacy operating UK Weight Loss Reviews to ensure their ads made their commercial intent clear and did not falsely claim or imply they were acting for purposes outside their trade, for example, by presenting accounts used for marketing purposes as independent review sites in paid-for ads. We also told them not to promote POMs to the public in future.
